New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2012
16:05 EDTCRISCuris initiated with an Outperform at BMO Capital
Target $8.
News For CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use